DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 203168
NDA 203168 describes PROLENSA, which is a drug marketed by Bausch And Lomb and is included in one NDA. It is available from one supplier. There are eight patents protecting this drug and one Paragraph IV challenge. Additional details are available on the PROLENSA profile page.
The generic ingredient in PROLENSA is bromfenac sodium. Five suppliers are listed for this compound. Additional details are available on the bromfenac sodium profile page.
The generic ingredient in PROLENSA is bromfenac sodium. Five suppliers are listed for this compound. Additional details are available on the bromfenac sodium profile page.
Summary for 203168
| Tradename: | PROLENSA |
| Applicant: | Bausch And Lomb |
| Ingredient: | bromfenac sodium |
| Patents: | 8 |
| Therapeutic Class: | Ophthalmic Agents |
Pharmacology for NDA: 203168
| Ingredient-type | Nonsteroidal Anti-inflammatory Compounds |
| Mechanism of Action | Cyclooxygenase Inhibitors |
Suppliers and Packaging for NDA: 203168
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| PROLENSA | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 203168 | NDA | Bausch & Lomb Incorporated | 24208-602 | N | 24208-602-06 |
| PROLENSA | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 203168 | NDA | Bausch & Lomb Incorporated | 24208-602 | N | 24208-602-03 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | EQ 0.07% ACID | ||||
| Approval Date: | Apr 5, 2013 | TE: | RLD: | Yes | |||||
| Patent: | ➤ Sign Up | Patent Expiration: | Sep 11, 2025 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | ➤ Sign Up | Patent Expiration: | Jan 16, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ➤ Sign Up | Patent Expiration: | Jan 16, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
